This morning, Prilenia announced that SV Health Investors has joined the Series B round as the company prepares for ALS and HD data readouts in the next 12 months. For more information, please see below prilenia.com/sv-health-inve…

We're pleased to announce the addition of our new controller Riccardo! Before joining Amplitude, Riccardo was the Shared Services Controller at CellCarta, a global CRO Welcome to the team Rick! linkedin.com/feed/update/ur…

We're now accepting applications for our 2023 Fellowship. Check out the information below and please pass it on to anyone who would be interested!

Happy International Women's Day from the Amplitude team! Today we celebrate the amazing and diverse women at Amplitude and within our portfolio companies who continue to inspire and do great things every day.

Huge congratulations to Abdera Therapeutics on their $142M US Series A + B Financing. Another example of world-class innovation advancing forward for patients. For our thoughts on the company, please see our blog post below - amplitudevc.medium.com/abdera-therape…

Our revolutionary antibody platform company, Radiant Biotherapeutics, leading the new frontier of multi-valent, multi-specific therapeutics emerging from stealth with an $8M seed round and multiple strategic partnerships. link.medium.com/SFKeYhsThzb

Congratulations to the Evommune team on their funding round to bring new therapies to treat serious inflammatory diseases. We are pleased to work with the stellar team and add the company to the Amplitude portfolio. For more of our thoughts, see below: amplitudevc.medium.com/evommune-bring…

This morning, one of our portfolio companies, Valence Labs, was acquired by Recursion for $47M US. Congratulations to Dan, Therence and the Valence team on building a world-leading AI computational chemistry platform company!

We are excited to join forces with Evotec to turbocharge precision medicine with the launch of our new venture studio, Pre-Amp! This partnership integrates Amplitude's expertise in venture creation with Evotec's industrialized drug discovery platforms evotec.com/en/investor-re…

We are excited about launching Reverb Therapeutics from stealth mode! Reverb is building its Amplifier platform, a first-in-class approach that amplifies endogenous cytokines and directs them to tissues of interest. To learn more, see here - linkedin.com/feed/update/ur…

Big announcement today with Amplitude portfolio company, Radiant Biotherapeutics receiving a grant from The Bill and Melinda Gates Foundation to advance the Multabody™ platform against HIV. Congrats! businesswire.com/news/home/2023…

We are expanding our team and are looking for an Investor to join us in Alberta! Ideal candidates will have at minimum a Master's degree in science, experience in business, and exposure to AI and ML See below for more information linkedin.com/feed/update/ur…

.Amplitude Ventures closes $263 million for second precision medicine VC fund. #healthtech #CDNtech betakit.com/amplitude-vent…

We are pleased to announce the $263M final close of our second Precision Medicine fund to build companies at the intersection of AI/ML and Biology Read more below amplitudevc.medium.com/a-new-chapter-…

Thanks to Sean Silcoff and The Globe and Mail for featuring us in their latest article